ATE496922T1 - Mglur1-antagonisten als therapeutische wirkstoffe - Google Patents
Mglur1-antagonisten als therapeutische wirkstoffeInfo
- Publication number
- ATE496922T1 ATE496922T1 AT06848624T AT06848624T ATE496922T1 AT E496922 T1 ATE496922 T1 AT E496922T1 AT 06848624 T AT06848624 T AT 06848624T AT 06848624 T AT06848624 T AT 06848624T AT E496922 T1 ATE496922 T1 AT E496922T1
- Authority
- AT
- Austria
- Prior art keywords
- antagonists
- glutamate receptor
- compounds
- metabotropic glutamate
- therapeutic agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/301,672 US7598259B2 (en) | 2004-06-15 | 2005-12-13 | mGluR1 antagonists as therapeutic agents |
| PCT/US2006/046943 WO2007070393A2 (en) | 2005-12-13 | 2006-12-11 | Mglur1 anatgonists as therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE496922T1 true ATE496922T1 (de) | 2011-02-15 |
Family
ID=38163430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06848624T ATE496922T1 (de) | 2005-12-13 | 2006-12-11 | Mglur1-antagonisten als therapeutische wirkstoffe |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7598259B2 (de) |
| EP (1) | EP1966220B1 (de) |
| JP (1) | JP2009519337A (de) |
| CN (1) | CN101437828A (de) |
| AT (1) | ATE496922T1 (de) |
| CA (1) | CA2633093A1 (de) |
| DE (1) | DE602006019911D1 (de) |
| WO (1) | WO2007070393A2 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598259B2 (en) * | 2004-06-15 | 2009-10-06 | Schering Corporation | mGluR1 antagonists as therapeutic agents |
| PE20060526A1 (es) * | 2004-06-15 | 2006-07-13 | Schering Corp | Compuestos triciclicos como antagonistas de mglur1 |
| WO2006081072A1 (en) * | 2005-01-24 | 2006-08-03 | Abbott Laboratories | Antagonists of the mglu receptor and uses thereof |
| US7767815B2 (en) * | 2005-08-19 | 2010-08-03 | Schering Corporation | Fused tricyclic mGluR1 antagonists as therapeutic agents |
| US7482360B2 (en) * | 2005-09-23 | 2009-01-27 | Schering Corporation | Fused tetracyclic mGluR1 antagonists as therapeutic agents |
| PE20081354A1 (es) * | 2006-11-30 | 2008-11-14 | Genentech Inc | Compuestos de azaindolilo como inhibidores de mek |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| WO2014011906A2 (en) * | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2014011902A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CA2890911A1 (en) | 2013-01-10 | 2014-07-17 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| KR102153040B1 (ko) | 2013-11-28 | 2020-09-07 | 삼성전자주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| GB201401886D0 (en) | 2014-02-04 | 2014-03-19 | Lytix Biopharma As | Neurodegenerative therapies |
| SG11201804901WA (en) | 2015-12-22 | 2018-07-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| EA201992780A1 (ru) | 2017-06-21 | 2020-06-02 | ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи | Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания |
| US12391705B2 (en) | 2018-12-19 | 2025-08-19 | Shy Therapeutics, Llc | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| WO2023081800A1 (en) * | 2021-11-05 | 2023-05-11 | The Regents Of The University Of California | Alpha-2a adrenergic receptor modulators and uses thereof |
| JP2025528113A (ja) * | 2022-08-10 | 2025-08-26 | ベルブルック ラボズ，エルエルシー | 治療剤としてのｃＧＡＳ活性の阻害剤 |
| WO2024097972A2 (en) * | 2022-11-04 | 2024-05-10 | Cedars-Sinai Medical Center | Compounds and methods for treating cancers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| SV2002000205A (es) | 1999-11-01 | 2002-06-07 | Lilly Co Eli | Compuestos farmaceuticos ref. x-01095 |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| WO2002062803A1 (en) | 2001-02-08 | 2002-08-15 | Yamanouchi Pharmaceutical Co., Ltd. | Thienopyrimidine derivative |
| DE60325051D1 (de) | 2002-06-06 | 2009-01-15 | Boehringer Ingelheim Pharma | SUBSTITUIERTE 3-AMINO-THIENO(2,3-b)PYRIDINE-2-AMIDE UND HERSTELLUNGSVERFAHREN SOWIE DEREN VERWENDUNG |
| DE60323765D1 (de) * | 2002-12-17 | 2008-11-06 | Schering Corp | Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten |
| US7598259B2 (en) | 2004-06-15 | 2009-10-06 | Schering Corporation | mGluR1 antagonists as therapeutic agents |
| PE20060526A1 (es) * | 2004-06-15 | 2006-07-13 | Schering Corp | Compuestos triciclicos como antagonistas de mglur1 |
| WO2006081072A1 (en) | 2005-01-24 | 2006-08-03 | Abbott Laboratories | Antagonists of the mglu receptor and uses thereof |
-
2005
- 2005-12-13 US US11/301,672 patent/US7598259B2/en not_active Expired - Fee Related
-
2006
- 2006-12-11 EP EP06848624A patent/EP1966220B1/de active Active
- 2006-12-11 CN CNA2006800527795A patent/CN101437828A/zh active Pending
- 2006-12-11 DE DE602006019911T patent/DE602006019911D1/de active Active
- 2006-12-11 JP JP2008545679A patent/JP2009519337A/ja not_active Withdrawn
- 2006-12-11 WO PCT/US2006/046943 patent/WO2007070393A2/en not_active Ceased
- 2006-12-11 AT AT06848624T patent/ATE496922T1/de not_active IP Right Cessation
- 2006-12-11 CA CA002633093A patent/CA2633093A1/en not_active Abandoned
-
2009
- 2009-01-21 US US12/356,867 patent/US7989464B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007070393A2 (en) | 2007-06-21 |
| US7989464B2 (en) | 2011-08-02 |
| CN101437828A (zh) | 2009-05-20 |
| DE602006019911D1 (de) | 2011-03-10 |
| EP1966220A2 (de) | 2008-09-10 |
| US20060167029A1 (en) | 2006-07-27 |
| EP1966220B1 (de) | 2011-01-26 |
| CA2633093A1 (en) | 2007-06-21 |
| US20090192178A1 (en) | 2009-07-30 |
| WO2007070393A3 (en) | 2007-10-25 |
| US7598259B2 (en) | 2009-10-06 |
| JP2009519337A (ja) | 2009-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200609231A (en) | Mglur1 antagonists as therapeutic agents | |
| WO2007038209A3 (en) | Fused tetracyclic mglur1 antagonists as therapeutic agents | |
| ATE496922T1 (de) | Mglur1-antagonisten als therapeutische wirkstoffe | |
| MA31117B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
| MA32898B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone | |
| UY28817A1 (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegerativos | |
| MA28935B1 (fr) | Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite | |
| CY1109069T1 (el) | Ενωσεις ιμιδαζοπυριδαζινης | |
| EA200800100A1 (ru) | Соединения азаиндазола и способы применения | |
| EA200801934A1 (ru) | 1,4-двузамещённые 3-циано-пиридоновые производные и их применение в качестве позитивных модуляторов рецепторов mglur2 | |
| EA200802054A1 (ru) | Ингибиторы фермента | |
| ATE345329T1 (de) | Pyridinderivate als modulatoren des cb2-rezeptors | |
| ATE402935T1 (de) | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen | |
| ECSP055719A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| EA200802020A1 (ru) | Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1 | |
| MA31567B1 (fr) | Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique | |
| ATE392471T1 (de) | Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren | |
| ATE552257T1 (de) | Positive allosterische chinolizidinon-m1- rezeptormodulatoren | |
| EP1817312A4 (de) | Makrozyklische aminiopyridyl-beta-sekretase-hemmer zur behandlung von morbus alzheimer | |
| TW200738733A (en) | Fused tricyclic mGluR1 antagonists as therapeutic agents | |
| TW200740826A (en) | Fused tricyclic mGluR1 antagonists as therapeutic agents | |
| ATE407119T1 (de) | Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors | |
| ECSP088280A (es) | Compuestos de imidazol para el tratamiento de trastornos neurológicos | |
| ATE466853T1 (de) | Cgrp-rezeptorantagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |